Skip to main navigation
  • Careers
  • Partnerships & Business Development
  • Contact Us
Link to  Esperion Therapeutics, Inc. Homepage
  • Company
    • About Us
    • Ethics and Compliance
  • Products
  • Science
    • Unmet Need
    • Scientific Resources
    • Pipeline
    • Grants
  • Newsroom

Newsroom

Esperion Therapeutics Offers Short-Term Option for Diuretic Management Before Escalation to IV for Patients With Heart Failure
Sep 30, 2026
PDF Version
Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026
May 26, 2026
PDF Version
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 14, 2026
PDF Version
Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026
May 13, 2026
PDF Version
Esperion to be Acquired by ARCHIMED
May 01, 2026
PDF Version
  • Current page 1
  • Page 2
  • Page 3
  • …
  • Next page ›
  • Last page »

Media Information

To speak with a member of our PR team, or to schedule an interview, please contact Esperion Corporate Communications by phone at +1 734-887-3903, or by email at corporateteam@esperion.com.


Corporate Inquiries & Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438


Email Alerts

  • OUR COMPANY
  • About Us
  • Ethics and Compliance
  • PRODUCTS
  • SCIENCE
  • Unmet Need
  • Scientific Resources
  • Pipeline
  • Grants
  • CAREERS
  • Partnerships & Business Development
  • Newsroom
  • Contact Us
Great place to work certified | JUN 2024 - JUN 2025 | USA

All trademarks and trade names are the property of their respective owners.

© 2026 Esperion Therapeutics, Inc. All rights reserved.

  • Privacy Policy
  • Terms of Use
  • Accessibility Statement
  • Social Media Community Guidelines
  • facebook
  • instagram
  • linkedin
  • twitter
  • rss
Search Investors